HLB Group Draws Global Attention with AACR Plenary Oral Presentation... Unveils Four Research Studies

SynKIR-110 Clinical Results to Be Unveiled in Conference Plenary Session

HLB Group announced that it will present four research outcomes at the American Association for Cancer Research (AACR 2026), the world's largest cancer research conference, to be held in San Diego, USA, starting from April 17, 2026 (local time).

According to the official AACR program released on March 17, three research papers from Verismo Therapeutics, a subsidiary of HLB Innovation, and one paper from Elevar Therapeutics, a subsidiary of HLB, have been listed.

First, the interim Phase 1 (STAR-101) results of Verismo's chimeric antigen receptor T-cell (CAR-T) therapy 'SynKIR-110' for solid tumors have been selected for an oral presentation. Notably, this study has also been included in the plenary session, where only research with significant impact and meaning is curated, underscoring both the clinical value of the study and the high level of attention it is receiving at this global conference.

This study will be presented on the fourth day of the conference, April 20, 2026. The presenter will be Janos L. Tanyi, Professor at the Perelman School of Medicine, University of Pennsylvania, who is leading the STAR-101 clinical trial.

Preclinical results for the blood cancer-targeted CAR-T therapy 'SynKIR-310' have also been selected for a poster presentation. The study is set to report that SynKIR-310 demonstrated superior antitumor effects compared to CD3-based conventional CAR-T in a B-cell non-Hodgkin's lymphoma xenograft mouse model, and that early clinical signals support the potential for future clinical development.

As successive preclinical results showing superiority over existing approved blood cancer CAR-T therapies are presented at the global conference, SynKIR-310's competitiveness continues to be validated. Expectations are also rising for the ongoing Phase 1 clinical trial of blood cancer CAR-T.

In addition, preclinical data on EGFR-targeted KIR-CAR for glioblastoma treatment, developed in collaboration with research teams from the University of Pennsylvania, will be presented as a poster. This study presents preclinical results showing meaningful antitumor effects in resistant glioblastoma models, overcoming the limitations of existing CAR-T therapies. It has garnered attention for demonstrating the differentiation and expandability of Verismo's proprietary 'KIR-CAR' platform technology.

Elevar will also release, through a poster presentation, an analysis comparing the high selectivity of the FGFR2-targeted anticancer drug 'Rilafugratinib' with existing pan-FGFR inhibitors.

Nam Kyung Sook, Executive Director of the Bio Strategy Planning Team at HLB Group, stated, "This AACR 2026 presentation marks an important milestone, demonstrating that the competitiveness of HLB Group's major pipelines—such as SynKIR-based cell therapies and FGFR2-targeted anticancer drugs—is being substantiated through clinical and preclinical data. Moving forward, we will continue to solidify our position in the global market, leveraging our accumulated data."

This content was produced with the assistance of AI translation services.